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Hyaluronic Acid Fillers: Where  




Since the approval of the United States’ first hyaluronic acid (HA) filler in 
December 2003, HA fillers have become mainstays of soft tissue augmentation due 
to their favorable safety profile and minimally invasive treatment nature. The past 
two decades have not only brought an expansion in the popularity of HA fillers, 
but also in the number of available HA filler products and indications for cosmetic 
enhancement. Accordingly, HA filler injection has become one of the most com-
monly performed cosmetic procedures worldwide. The progression of HA filler 
products is a study in both biomedical engineering advancements, as well as evolv-
ing concepts of beauty and cosmesis. In this chapter, we review the history of these 
products, including their composition and indications for use. We then explore the 
prospect of HA fillers for the future of esthetic medicine, as they remain a vital 
component of nonsurgical soft tissue augmentation.
Keywords: soft tissue augmentation, biomedical engineering, cosmetic dermatology, 
hyaluronic acid
1. Introduction
Although typically thought of as outgrowths of modern medicine, interventions 
for esthetic and cosmetic purposes are well documented through multiple civiliza-
tions across history. In the non-surgical arena, soft tissue augmentation rapidly 
accelerated with the first reports of autologous fat transfer in the late 19th century; 
concomitantly, reports began to emerge from Europe on the use of injectable paraf-
fin for rhytide reduction and soft tissue rejuvenation [1]. Shortly after the spread 
of paraffin injections across Europe and Asia, reports of embolic complications, as 
well as late-onset granulomatous reactions (later called ‘paraffinomas’) led to their 
eventual removal from the realm of esthetic practice, although non-medical/illicit 
injection of paraffin-containing substances still remain a sporadic issue in clinical 
practice today.
It was not until the 1940s that a new injectable agent found widespread use. 
Silicone, a dimethylsiloxane polymer, first entered clinical practice in Japan as an 
agent for breast augmentation. Over the following twenty years, silicone found 
widespread popularity across the United States, with the Dow Corning Corporation 
developing an injectable form of the material in the mid-1960s. As with paraffin 
decades prior, reports began to emerge in the 1960s–70s of delayed granulomatous 
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reactions to injected silicone. Termed siliconomas, these entities displayed a similar 
inflammatory pattern to paraffin, although migration of silicone due to the effects 
of gravity often led to granuloma formation at a site inferior or distal to the original 
site of injection [2]. As with paraffin, illicit silicone injection remains an issue across 
the world today, and clinicians should be mindful of this entity in the evaluation of 
granulomatous reactions following non-medical cosmetic treatments.
In 1981, the cosmetic landscape advanced with the United States Food and Drug 
Administration’s (FDA) approval of Zyderm™, the first injectable filler approved 
for facial cosmetic enhancement. Derived from bovine collagen, Zyderm™ was 
comprised of a matrix of type I and type III collagen, which later formulations 
(Zyplast™) cross-linked with glutaraldehyde in order to slow the degradation of 
injected material [2]. Unlike the relatively inert nature of both paraffin and silicone, 
bovine collagen poses a significant risk of hypersensitivity reactions (3–3.5%, per 
population estimates) due to cross-speciation. Accordingly, skin testing prior to 
injection was necessary for all patients. Furthermore, although the collagen used for 
injection was derived from a closed and closely surveilled group of bovines, public 
concern regarding bovine spongiform encephalopathy (“mad cow disease”) led to 
its fall from favor across the following decades [2].
The modern cosmetic injectables revolution found its genesis in 2003, when the 
FDA approved Restylane™, its first hyaluronic acid (HA) product. While other 
non-HA fillers were approved by the FDA for use in the following years – poly-L-
lactic acid (Sculptra™), polymethylmethacrylate (Belafill™), and Radiesse™ (cal-
cium hydroxylapatite) among the most commercially successful – HA fillers have 
risen as some of the most popular agents available for nonsurgical facial cosmesis.
2. Hyaluronic acid fillers: derivatives and bioengineering
Hyaluronic acid is a glycosaminoglycan, a type of acid mucopolysaccharide that 
demonstrates significant hydrophilicity and serves as a key portion of the extracel-
lular matrix of all organisms. In skin, HA is a key component of “ground substance”, 
the acellular material found in the extracellular environment around collagen 
bundles of the dermis. In its structural support of collagen and elastin fibers, HA’s 
main role in skin is to lubricate these extracellular structures by attracting water, 
which in turn produces a volumizing effect in the skin [3].
With time, the amount of HA in the dermis begins to diminish; accordingly, 
a hallmark of aging skin is a loss of both volume and elasticity. To this effect, HA 
fillers rose as a safe and logical solution for facial soft tissue enhancement: by 
reinstating the HA balance of the dermis, HAs draw water into the extracellular 
environment and lead to significant improvements in rhytide and soft tissue [2, 4]. 
Furthermore, due to HA’s ubiquitous nature as a ‘native component’ of skin, the 
immunogenicity of HA filler products remains extremely low.
Engineering of HA fillers is possible through two broad methods: animal-
derived and bacterial-derived HAs. In the animal-derived group, HA is extracted 
from rooster combs and used for cosmetic injection [5]. Among the most suc-
cessful in this group is Hylaform™, although animal-derived HAs have fallen 
from popularity due to their relatively shorter duration of effect, as well as their 
slightly increased immugenicity as compared to bacterial-derived HAs [1, 2]. In the 
bacterial-derived group, HAs are typically generated by fermentation of nonanimal 
stabilized hyaluronic acid (NASHA) from streptococcal species (Restylane™, 
Juvederm™, Captique™, Hydrelle™).
Two unique variables that determine an HA filler’s physical properties are 
gel particle size, as well as the degree of HA crosslinking present. This is best 
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exemplified by the Restalyne™ and Juvederm™ line of HA fillers, where adjust-
ments in these two variables are used to create novel products with different 
properties and clinical applications. While many other HA filler products are 
commercially available, further analysis of this line of HA filler agents is chosen due 
to their ubiquitous presence in cosmetic offices worldwide.
Alterations in gel particle size are a hallmark of the Restylane™ family of 
products: products featuring particles of lower molecular weight (350 μm for 
Restylane™ versus 800-900 μm for Restylane™Lyft [formerly known as Perlane]) 
allow for a higher density of gel particles per unit volume (100,000 particles/
milliliter for Restylane™ versus 8,000 particles/milliliter for Restylane™Lyft). This 
is engineered through a process of sieving – by filtering particles mechanically, 
products are created with gel particles of a singular size [6]. Accordingly, while 
small gel particle-based products such as Restylane™, Restylane™-L, Restylane™ 
Kysse, and Restylane™ Silk have been approved for applications ranging from 
midface to lip and perioral augmentation, larger gel particle products such as 
Restylane™ Defyne, Restylane™ Refyne, and Restylane™ Lyft has been typically 
employed for deep rhytide correction and volumization of the cheeks and 
midface. Notably, Restylane™ Lyft also carries FDA approval for dorsal hand 
rejuvenation [1, 6, 7].
The effects of varying degrees of crosslinking are best displayed by the 
Juvederm™ family of products. Generally speaking, the greater the degree of 
crosslinking, the greater the degree of water absorption demonstrated by the 
filler; accordingly, more crosslinked products are typically used when significant 
volumizing or deep rhytide correction is desired. In contrast to Restalyne, which 
maintains the same concentration of hyaluronic acid throughout its product line, 
Juvederm™ products feature varying concentration of hyaluronic acid (24 mg/mL 
for Juvederm Ultra, Juvederm Ultra Plus, Juvederm Ultra XC, and Juvederm Ultra 
Plus XC; 20 mg/mL for Juvederm Voluma; 17.5 mg/mL for Juvederm Vollure; 15 mg/
mL for Juvederm Volbella). In addition, these products also differ from each other 
in both their percentage of HA crosslinking, as well as the manner in which they are 
crosslinked [8, 9].
Juvederm Ultra, Ultra Plus, and their XC variants feature a patented crosslinking 
technology termed Hylacross. With Hylacross, HAs of the same molecular weight 
are crosslinked together, creating a relatively uniform product of set viscosity and 
thickness. This is in contrast to Juvederm Voluma, Vollure, and Volbella, which use 
another patented technology called Vycross crosslinking. Vycross-generated fillers 
feature HAs of varying molecular weight, resulting in products that are reported to 
have a greater number of applications across the face, as well as a longer duration of 
action due to non-uniform degradation [8, 10].
Together, it is gel particle size and density, as well as degree/type of HA cross-
linking, that influence the G’, or elastic modulus, of HA fillers. G’ is a measure 
of a filler’s response to shear or dynamic forces: the higher the G’ of a filler, the 
greater its resistance to deformation or movement when under the influences of 
external force (such as dynamic facial movement). Accordingly, fillers with higher 
G’ are often used for their volumizing and lifting effects, and deeper injections are 
needed [9, 11].
Emblematic of the role of G’ in filler applications, Belotero Balance (Merz 
Esthetics) is a HA filler product that relies on a greater density of non-crosslinked 
HA in order to produce its intended effect. Generally speaking, the strength and 
volumizing effect of fillers is directly related to its degree of HA crosslinking – that 
is, free HAs are non-contributory to the strength, volumizing, or lifting poten-
tial of a filler product. Through a novel, patented formulation called Cohesive 
Polydensified Matrix – a process that generates a varying degree of crosslinked 
Extracellular Matrix - Developments and Therapeutics
4
HA in suspension with free HAs – a product is produced that features a signifi-
cantly lower G’ than other HA products (G’ = 30 for Belotero Balance; G’ = 545 for 
Restylane™ Lyft). Accordingly, Belotero ™ Balance is able to be used in both the 
intradermal and superficial subcuticular planes, with lower risk of the Tyndall 
effect (a gray-blue discoloration secondary to light scattering from superficially 
placed filler products) as compared to other HA fillers [9, 11, 12].
Depending on the product used, as well as the location being treated, HA fillers 
typically augment treated soft tissues for a period of 6–18 months. As compared to 
bovine collagen, hypersensitivity reactions are exceedingly rare, estimated at 1 in 
every 5000 injections. A notable benefit of these products, as compared to non-HA 
fillers, is their reversibility: if dissolution of filler is needed, injectable hyaluroni-
dase may be used.
3. Hyaluronic acid fillers: directions for the future
Given their widespread success and popularity, HA fillers are likely to remain a 
mainstay in the cosmetic proceduralist’s toolbox. Innovations in the field – ranging 
from methods of biochemical engineering to novel techniques for injection and 
treatment – all lend great promise to the future of HA fillers in esthetic practice.
In the realm of product development, one such advancement is demonstrated 
by Teosyal ™, an HA filler approved by the FDA in 2017. Through a novel patented 
synthesis method, a product with a lower bacterial protein and endotoxin load (as 
compared to other HA fillers) is generated, with a reported lower risk of potential 
hypersensitivity reactions as a result [9]. Another product generated through a 
unique method of synthesis is the Neauvia ™ family of HA fillers. Marketed as a 
‘fully organic’ product, Neauvia ™ HAs are not synthesized from the streptococ-
cal species typical of other HA fillers, but instead by Bacillus subtilis, a bacterium 
widely used in probiotic supplements. These HAs are then crosslinked with poly-
ethylene glycol, creating a biocompatible hydrogel [13]. Lastly, Juvederm ™ has 
recently introduced Volux, a thicker HA with a concentration of 25 mg/mL, for 
lower face (jawline and chin) augmentation.
Continuing improvements in injection technique also offer a promising future 
of HA filler use. Blunt-tipped cannulas are rising in popularity as an alternative 
to hypodermic needles, as their use is associated with a statistically signifi-
cant decrease in bruising, as well as lower pain associated with injection [14]. 
Additionally, cadaveric studies comparing blunt-tipped cannulas to sharp needles 
demonstrated a higher risk of intra-arterial injection with sharp needles, as well as 
a greater degree of filler extrusion across multiple anatomic planes (as opposed to 
one targeted level of injection) with needles as compared to blunt-tipped cannulas 
[15]. Accordingly, the use of cannulas has greatly advanced the technique, safety 
profile, and resultant cosmetic effect of HA fillers to areas such as the tear troughs 
and jawline, where anatomic plane precision is critical.
Exactness in volumetric dosing is highly dependent on injector experience, as 
elements such as HA filler viscosity, needle gauge, and plane/site of injection all 
influence the force needed to inject a bolus of filler agent. To elevate this aspect of 
treatment beyond volume marking on syringes and “injector feel” while introduc-
ing a bolus, Restylane ™ has recently introduced Skinboosters, a microdroplet HA 
treatment that uses a SmartClick® syringe to provide metered doses with each 
depression of the syringe plunger [16]. This technology has especially shown great 
promise when injecting into more superficial planes, as improper or non-uniform 
technique may otherwise result in nodule or ‘lump’ formation, as well as the 
Tyndall effect.
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4. Conclusions
Hyaluronic acid fillers are essential component of the cosmetic proceduralist’s 
armamentarium. Their ubiquitous presence in clinics across the world, as well as 
their widespread acceptance by the general public, has made awareness of their use 
important for all clinicians. An understanding of their unique properties and physi-
cal features provides esthetic practitioners with a better comprehension of their 
treatment indications, potential complications, and treatment pitfalls, as well as an 
appreciation of developments on the horizon for future HA fillers.
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